SBIR-STTR Award

Spectroscopic high throughput identification of protein variants
Award last edited on: 7/8/2010

Sponsored Program
SBIR
Awarding Agency
DOD : CBD
Total Award Amount
$70,000
Award Phase
1
Solicitation Topic Code
CBD09-104
Principal Investigator
Steven M Ebstein

Company Information

Lexitek Inc

14 Mica Lane Suite 6
Wellesley, MA 02481
   (781) 431-9604
   info@lexitek.com
   www.lexitek.com
Location: Single
Congr. District: 05
County: Norfolk

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2009
Phase I Amount
$70,000
Quantitative Raman spectroscopy offers a means of estimating concentrations of protein variants. The Raman spectrum can be a fingerprint of an individual molecule and features unique to functional groups. In conjunction with robust data analysis such as principal component analysis (PCA), chemometric assessment of a sample can be performed. As an optical technique, this approach can yield high-throughput with robust instrumentation that can be deployed in the field. Some facets of instrument miniaturization have already been accomplished. In order to deal with realistic sample sizes, surface enhanced Raman spectroscopy (SERS) can be employed. Using this approach, we propose to develop instrumentation for reproducible, high-throughput protein variant quantitation. Our approach relies on a proprietary substrate Lexitek is developing for SERS that can be inexpensively fabricated and is uniform and reproducible. The substrate has high enhancement and the unique capability for doing separation and detection in situ. As any amount of admixture separation increases the SNR of the chemometric process, our approach has a dimension not shared by other SERS assays that will enable development of a range of assays for protein variants.

Keywords:
Protein Variant, Polymorphism, Quantitative Spectroscopy, Surface-Enhanced Raman Scattering, Molecular Diagnostics, Proteomics

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
----
Phase II Amount
----